ResultsIQ

ResultsIQ › Latest results › Sanofi India Limited

Sanofi India Limited Q4 FY25 earnings call summary

NSE: SANOFI · BSE: 500674

Earnings call of 26 Feb 2026, summarised by AI from the filing.

Sanofi India FY25 domestic sales ₹1,511 cr; Q4 EBITDA margin 21.5%, partnership fluctuation to continue in 2026.

Key takeaways

  1. Guidance Partnership fluctuation to continue in 2026; stabilization expected by end of 2026.
  2. Driver Diabetes franchise growth: insulin plus 6% FY25, Q4 close to 11%.
  3. Risk Aggressive discounting by competition in institutional business.

Original filing on BSE

Sanofi India Limited Q1 FY27 results

As filed: Revenue ₹438 cr (+8% year on year), EBITDA ₹115 cr (+23% year on year), PAT ₹83.5 cr (+19% year on year), EBITDA margin 26.3% (+319 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹472 cr (−12% year on year), EBITDA ₹143 cr (−17% year on year), PAT ₹103 cr (−15% year on year), EBITDA margin 30.2% (−185 bps). Score 29 of 100, Below trend. Revenue and profit growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 185 bps year on year. Share price after the results: −7.1% in 29 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹420 cr (−18% year on year), EBITDA ₹90.3 cr (−23% year on year), PAT ₹61.7 cr (−32% year on year), EBITDA margin 21.5% (−140 bps). Score 23 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 140 bps year on year. Revenue fell 12% from last quarter. Share price after the results: −22.8% in 30 days (Nifty 500: −10.2%).
  • Q2 FY26: Revenue ₹475 cr (−9% year on year), EBITDA ₹133 cr (+11% year on year), PAT ₹76.0 cr (+14% year on year), EBITDA margin 28.0% (+510 bps). Score 58 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were above it. EBITDA margin rose 510 bps year on year. Share price after the results: −7.6% in 30 days (Nifty 500: +0.5%).
  • Q1 FY26: Revenue ₹406 cr (−13% year on year), EBITDA ₹94.0 cr (−18% year on year), PAT ₹70.0 cr (−32% year on year), EBITDA margin 23.2% (−163 bps). Score 29 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 163 bps year on year. Revenue fell 24% from last quarter. Share price after the results: −11.7% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹536 cr (−27% year on year), EBITDA ₹172 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 32.1% (+231 bps). Score 34 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 231 bps year on year. Share price after the results: +1.7% in 30 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹515 cr (−26% year on year), EBITDA ₹118 cr (−37% year on year), PAT ₹91.0 cr (−34% year on year), EBITDA margin 22.9% (−403 bps). Score 4 of 100, Below trend. EBITDA margin fell 403 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹524 cr (−27% year on year), EBITDA ₹120 cr (−42% year on year), PAT ₹82.0 cr (−46% year on year), EBITDA margin 22.9% (−619 bps). Score 2 of 100, Below trend. EBITDA margin fell 619 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Sanofi India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.